ストックスクリーナーアプリを入手
0.9459
6.40%
0.0569
プレマーケット:
.94
-0.0059
-0.62%
前日終値:
$0.889
開ける：
$0.87
24時間の取引高:
1.12M
Relative Volume:
7.71
時価総額：
$23.93M
収益：
-
当期純損益:
$-39.22M
株価収益率:
-0.5331
EPS:
-1.7742
ネットキャッシュフロー:
$-17.31M
1週間 パフォーマンス:
+5.10%
1か月 パフォーマンス:
-14.78%
6か月 パフォーマンス:
-14.01%
1年 パフォーマンス:
+132.41%
1日の値動き範囲:
$0.8501
$0.9459
1週間の範囲:
$0.8134
$0.9459
52週間の値動き範囲:
$0.3788
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Compare AEON vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.9459 | 22.49M | 0 | -39.22M | -17.31M | -1.7742 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-18 | 開始されました | H.C. Wainwright | Buy |
AEON Biopharma Inc. (AEON) 最新ニュース
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - The Globe and Mail
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Singapore
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
New AEON finance chief gets stock awards tied to NYSE compliance - Stock Titan
Form 8-KCurrent report - ADVFN
AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan
AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma 2025 Financial Review - AlphaStreet
Stock Market Recap: Whats the profit margin of AEON Biopharma Inc - baoquankhu1.vn
AEON Biopharma reports biosimilar progress, secures financing By Investing.com - Investing.com Australia
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - The Manila Times
Can AEON Biopharma Inc keep up with sector leaders2026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
AEON Biopharma 2025 10-K: Net loss $39.2M, EPS $(3.95) - TradingView — Track All Markets
AEON Biopharma (AEON) advances Botox biosimilar plan but warns on going concern - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[8-K] AEON Biopharma, Inc. Reports Material Event - Stock Titan
AEON Biopharma reports biosimilar progress, secures financing - Investing.com
AEON's Botox biosimilar matched 3,400 amino acids as FDA mapped next steps - Stock Titan
Latest AEON NewsAEON Biopharma Presents Positive Results fr... - Stock Titan
AEON Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Biotech Landscape Update: Regulatory Approvals and Mergers - Intellectia AI
Aeon Biopharma announces FDA feedback after Type 2a meeting - Yahoo Finance
AEON Biopharma receives FDA feedback on botulinum toxin biosimilar - Investing.com
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - The Manila Times
FDA maps next steps for AEON's bid to bring a Botox biosimilar - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Aeon Biopharma (AEON) - Stock Titan
AEON Biopharma, Inc.: Fundamental Analysis and Financial Ratings | AEON | US00775E1029 - marketscreener.com
Technical Analysis: Whats the profit margin of AEON Biopharma Inc2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Travel Stocks: How much upside does AEON Biopharma Inc haveQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Profit Recap: Can AEON Biopharma Inc stock outperform in a bear marketMarket Performance Report & Low Risk Entry Point Guides - baoquankhu1.vn
Risk Analysis: Is AEON Biopharma Inc stock good for income investors2026 Trade Ideas & Safe Entry Point Identification - baoquankhu1.vn
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma (NASDAQ: AEON) CMO granted RSUs and modifies 1,316,872-unit award - Stock Titan
AEON Biopharma names John Bencich as chief financial officer - Investing.com Australia
AEON Biopharma Appoints John Bencich as Chief Financial Officer - The Manila Times
AEON Biopharma Strengthens Finance Leadership with New CFO - TipRanks
AEON Biopharma names John Bencich as chief financial officer By Investing.com - Investing.com Canada
AEON appoints John Bencich as CFO; Jennifer Sy employment terms confirmed - TradingView
AEON Biopharma Inc. (AEON) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):